PMID- 1793156
OWN - NLM
STAT- MEDLINE
DCOM- 19920402
LR  - 20191028
IS  - 0192-8562 (Print)
IS  - 0192-8562 (Linking)
VI  - 13
IP  - 3
DP  - 1991 Fall
TI  - Vincristine therapy for severe platelet alloimmunization.
PG  - 300-4
AB  - A 19-month-old girl with idiopathic severe aplastic anemia refractory to 
      multi-agent immunosuppressive therapy developed severe platelet alloimmunization 
      following several months of platelet transfusions. She became refractory to human 
      leukocyte antigen (HLA)-matched platelet transfusions and experienced frequent 
      episodes of bleeding. She was treated with intravenous vincristine administered 
      weekly for three doses and showed marked improvement in both clinical and 
      laboratory response to platelet transfusions. When vincristine was held for 3 
      weeks, she again became refractory to HLA-matched platelet transfusion. 
      Reinstitution of vincristine resulted in cessation of clinical bleeding and 
      improved response to platelet transfusion. The mechanism of response likely 
      involves selective delivery of cytotoxic drug to macrophages. To our knowledge 
      this is the first reported case of alloimmune thrombocytopenia responsive to 
      vincristine.
FAU - Bruggers, C S
AU  - Bruggers CS
AD  - Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 
      27710.
FAU - Kurtzberg, J
AU  - Kurtzberg J
FAU - Friedman, H S
AU  - Friedman HS
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Pediatr Hematol Oncol
JT  - The American journal of pediatric hematology/oncology
JID - 7908071
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunologic Factors)
RN  - 0 (Isoantibodies)
RN  - 5J49Q6B70F (Vincristine)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Anemia, Aplastic/complications
MH  - Antibody Formation/drug effects
MH  - Antilymphocyte Serum/therapeutic use
MH  - Blood Platelets/*immunology
MH  - Combined Modality Therapy
MH  - Cyclosporine/therapeutic use
MH  - Female
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use
MH  - Hemorrhagic Disorders/etiology
MH  - Humans
MH  - Immunization
MH  - Immunoglobulin G/*analysis
MH  - Immunologic Factors/therapeutic use
MH  - Infant
MH  - Isoantibodies/*analysis
MH  - Macrophages/drug effects
MH  - Megakaryocytes/drug effects
MH  - Pancytopenia/etiology/immunology/*therapy
MH  - Platelet Transfusion
MH  - Prednisone/therapeutic use
MH  - T-Lymphocytes
MH  - Thrombocytopenia/*drug therapy/etiology/immunology
MH  - *Transfusion Reaction
MH  - Vincristine/pharmacology/*therapeutic use
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 10.1097/00043426-199123000-00009 [doi]
PST - ppublish
SO  - Am J Pediatr Hematol Oncol. 1991 Fall;13(3):300-4. doi: 
      10.1097/00043426-199123000-00009.